Overview

Coxib-inhibition of Duodenal Polyp Growth in FAP

Status:
Terminated
Trial end date:
2004-04-01
Target enrollment:
0
Participant gender:
All
Summary
Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would stop or reverse the development of premalignant adenomatous lesions in the duodenal mucosa of FAP patients.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Oslo University Hospital
Treatments:
Rofecoxib
Criteria
Inclusion Criteria:

- FAP patient with previous colectomy and confirmed polyposis

Exclusion Criteria:

- Pregnancy

- Malignancy

- NSAID hypersensitivity